Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome

Blood

Volumn 121, Issue 21, 2013, Pages 4377-4387

  Saida, Satoshi ^a   Watanabe, Ken Ichiro ^a   Sato Otsubo, Aiko ^b   Terui, Kiminori ^c   Yoshida, Kenichi ^b   Okuno, Yusuke ^b   Toki, Tsutomu ^c   Wang, RuNan ^c   Shiraishi, Yuichi ^d   Miyano, Satoru ^d   Kato, Itaru ^a   Morishima, Tatsuya ^a   Fujino, Hisanori ^a   Umeda, Katsutsugu ^a   Hiramatsu, Hidefumi ^a   Adachi, Souichi ^a   Ito, Etsuro ^c   Ogawa, Seishi ^b   Ito, Mamoru ^e   Nakahata, Tatsutoshi ^f   Heike, Toshio ^a   more..

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d THE UNIVERSITY OF TOKYO   (Japan)

^e CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA; TRANSCRIPTION FACTOR GATA 1; GATA1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME DELETION; CONTROLLED STUDY; DOWN SYNDROME; GENE MUTATION; HUMAN; LEUKEMOGENESIS; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRELEUKEMIA; PRIORITY JOURNAL; TRANSIENT ABNORMAL MYELOPOIESIS; TUMOR XENOGRAFT; ANIMAL; BLOOD; CELL CULTURE; CLONAL EVOLUTION; DISEASE MODEL; EXCHANGE BLOOD TRANSFUSION; FEMALE; GENETICS; LEUKEMOID REACTION; MALE; MOUSE MUTANT; NEWBORN; PATHOLOGY; PHYSIOLOGY; XENOGRAFT;

ANIMALS; CELLS, CULTURED; CLONAL EVOLUTION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; EXCHANGE TRANSFUSION, WHOLE BLOOD; FEMALE; GATA1 TRANSCRIPTION FACTOR; HUMANS; INFANT, NEWBORN; LEUKEMIA, MYELOID; LEUKEMOID REACTION; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; PRELEUKEMIA; TRANSPLANTATION, HETEROLOGOUS;

MLCS; MLOWN;

EID: 84880603049     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-474387     Document Type: Article

References (42)

1. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110(6): 2128-2131.
2. Massey GV, Zipursky A, Chang MN, et al; Children's Oncology Group (COG). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107(12):4606-4613.
3. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9(2):139-149.
4. Hitzler JK. Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer. 2007; 49(7 Suppl):1066-1069.
5. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101(11):4301-4304.
6. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002; 32(1):148-152.
7. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet. 2003;361(9369):1617-1620.
8. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102(8):2960-2968.
9. Weiss MJ, Orkin SH. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci USA. 1995;92(21):9623-9627.
10. Ferreira R, Ohneda K, Yamamoto M, Philipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol. 2005; 25(4):1215-1227.
11. Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood. 1988;72(1):15-23.
12. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008; 111(3):1575-1583.
13. Xu G, Kato K, Toki T, Takahashi Y, Terui K, Ito E. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder. J Pediatr Hematol Oncol. 2006;28(10): 696-698.
14. Vyas P, Crispino JD. Molecular insights into Down syndrome-associated leukemia. Curr Opin Pediatr. 2007;19(1):9-14.
15. Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008;111(2): 767-775.
16. Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, Scott HS. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood. 2009;113(9): 1929-1937.
17. Alford KA, Slender A, Vanes L, et al. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood. 2010;115(14):2928-2937.
18. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012;122(3):948-962.
19. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.
20. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011;208(4): 653-661.
21. Notta F, Mullighan CG, Wang JCY, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011; 469(7330):362-367.
22. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356-361.
23. Hiramatsu H, Nishikomori R, Heike T, Ito M, Kobayashi K, Katamura K, Nakahata T. Complete reconstitution of human lymphocytes from cord blood CD341 cells using the NOD/SCID/gammacnull mice model. Blood. 2003;102(3):873-880.
24. Fujino H, Hiramatsu H, Tsuchiya A, et al. Human cord blood CD341 cells develop into hepatocytes in the livers of NOD/SCID/gamma(c)null mice through cell fusion. FASEB J. 2007;21(13):3499-3510.
25. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712-716.
26. Kato I, Niwa A, Heike T, et al. Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis. PLoS ONE. 2011;6(11):e27042.
27. Chen J, Li Y, Doedens M, Wang P, Shago M, Dick JE, Hitzler JK. Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome. Leukemia. 2010;24(5):1012-1017.
28. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175-3182.
29. Lacombe F, Durrieu F, Briais A, et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia. 1997;11(11): 1878-1886.
30. Suda J, Eguchi M, Akiyama Y, et al. Differentiation of blast cells from a Down's syndrome patient with transient myeloproliferative disorder. Blood. 1987;69(2):508-512.
31. Silva ML, do Socorro Pombo-de-Oliveira M, Raimondi SC, et al. Unbalanced chromosome 1 abnormalities leading to partial trisomy 1q in four infants with Down syndrome and acute megakaryocytic leukemia. Mol Cytogenet. 2009;2:7.
32. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
33. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103(7):2480-2489.
34. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.
35. Shimada A, Xu G, Toki T, Kimura H, Hayashi Y, Ito E. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood. 2004; 103(1):366.
36. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5(1):11-20.
37. Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome. Crit Rev Oncog. 2011;16(1-2): 25-36.
38. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.
39. Blink M, van den Heuvel-Eibrink MM, Aalbers AM, et al. High frequency of copy number alterations in myeloid leukaemia of Down syndrome. Br J Haematol. 2012;158(6):800-803.
40. Malkin D, Brown EJ, Zipursky A. The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genet Cytogenet. 2000;116(1):1-5.
41. Norton A, Fisher C, Liu H, et al. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 2007;110(3):1077-1079.
42. Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008;112(10):4220-4226.